Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash Flows From Operating Activities:
Net loss	$ (3,303,000)	$ (4,478,000)	$ (4,490,000)	$ (4,273,000)	$ (12,864,000)	$ (13,240,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation					407,000	346,000
Income tax benefit	(527,000)		(335,000)		(1,216,000)	(867,000)
Change in fair value of contingent consideration					(999,000)	(244,000)
Non-cash lease expense					283,000	137,000
Depreciation					96,000	60,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets					1,524,000	780,000
Deposits and other assets					(54,000)
Accounts payable					(74,000)	(504,000)
Accrued expenses					883,000	(326,000)
Accrued employee benefits					(129,000)	271,000
Operating lease liability					(312,000)	(127,000)
Net Cash Used In Operating Activities					(12,455,000)	(13,714,000)
Cash Flows from Investing Activities
Purchase of property and equipment					(146,000)	(25,000)
Cash paid for business combination, net of cash acquired						(3,863,000)
Pre-acquisition loan to VCN						(417,000)
Net Cash Used in Investing Activities					(146,000)	(4,305,000)
Cash Flows from Financing Activities
Payment of loans payable					(75,000)	(1,376,000)
Proceeds from issuance under at-the-market offering, net of issuance costs					2,157,000
Net Cash Provided by Financing Activities					2,082,000	1,358,000
Effects of exchange rate changes on cash and cash equivalents					(109,000)	(84,000)
Net decrease in cash and cash equivalents and restricted cash					(10,628,000)	(16,745,000)	$ (10,600,000)
Cash and cash equivalents and restricted at the beginning of this period		$ 41,885,000		$ 67,325,000	41,885,000	67,325,000	67,325,000
Cash and cash equivalents and restricted cash at the end of this period	31,257,000		50,580,000		31,257,000	50,580,000	41,885,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet
Cash and cash equivalents	31,160,000		50,490,000		31,160,000	50,490,000	41,786,000
Restricted cash included in other long-term assets	97,000		90,000		97,000	90,000
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 31,257,000		50,580,000		31,257,000	50,580,000	41,885,000
Supplemental non-cash investing and financing activities:
Right of use assets obtained in exchange for lease liabilities					$ 937,000
Fair value of contingent consideration issued in a business combination						12,158,000
Fair value of equity issued as consideration in a business combination						6,599,000
Effective settlement of pre-closing VCN financing						417,000
Goodwill measurement period adjustment						(884,000)
In-process R&D measurement period adjustment						810,000
Deferred tax liability measurement period adjustment						202,000
Effect of Warrant exercise price adjustment			$ 340,000			340,000	$ 340,000
Series C Preferred Stock
Cash Flows from Financing Activities
Proceeds from sale of series preferred stock, net of issuance cost						2,006,000
Series D Preferred Stock
Cash Flows from Financing Activities
Proceeds from sale of series preferred stock, net of issuance cost						$ 728,000